Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Neurological Devices Panel

This article was originally published in The Gray Sheet

Executive Summary

Cancels scheduled Jan. 28 meeting. Analysts note that the panel was expected to review Medtronic's Activa neurostimulation device for Parkinson's treatment (1"The Gray Sheet" Nov. 29, p. 15). Quarterly panel meetings in 2000 are tentatively scheduled on May 11-12, Aug. 17-18, and Nov. 16-17

You may also be interested in...

Medtronic Launches Dual-Channel Pain Reliever, Buys Certain Elekta Assets

Medtronic's Synergy dual-channel neurostimulation system for chronic intractable pain of the trunk and limbs is expected to account for roughly 25% of the company's neurostimulation business following its U.S. rollout Nov. 22, Medtronic says.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts